Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say
1. Eli Lilly's Q3 revenue rose 54%, beating expectations at $17.60 billion. 2. Adjusted EPS increased to $7.02 from $1.18 last year, surpassing analyst forecasts. 3. Goldman Sachs maintains a 'Buy' rating, raising price target to $951. 4. Lilly remains well-positioned amidst rising competition in obesity treatments. 5. BofA Securities also rates Lilly as 'Buy' with a focus on durable growth potential.